From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q1 2024 call → NOWe need to determine if management describes that the company has recently crossed into being an approved, specified, listed, qualified, registered, reimbursed, or pre-authorized choice inside buyers' own purchasing, reimbursement, formulary, specification, procurement, network, catalog, or program systems — so that a meaningful portion of future business can arrive without a discrete selling event for each order. And that this access is new enough that most volume is still ahead. Look for keywords: approved, listed, qualified, registered, reimbursed, pre-authorized, formulary, procurement, specification, etc. Also look for "recent" and "still ahead". In the transcript, management discusses various products. For NanoKnife, they mention PRESERVE study enrollment complete, data to be submitted to FDA in Q3 2024 for expanded indication. That is pending approval, not yet obtained. They also mention NICE upgrade in the UK (from previous call). But that is not described as recent on this call? They mention "we announced that NICE had upgraded our status in the U.K." That is a reference to a prior announcement. But is that a gateway? NICE is a UK health technology assessment body. Being upgraded might mean reimbursement or guidance. However, the transcript does not elaborate on what that means for purchasing. Also, they say "we think that also has a knock-on effect in other areas within Europe." That is not a concrete description of being placed into a system. For Auryon, they mention CE Mark expected in next few months. That is pending, not yet obtained. For AngioVac, they received Breakthrough Device Designation. That is a regulatory designation, not a purchasing pathway. It may facilitate approval but not a buyer-side system. For AlphaVac, they are awaiting PE indication, not yet approved. For mechanical thrombectomy, they talk about market share and adoption, but no mention of being listed on any formulary or procurement. The only thing that might qualify is the NICE upgrade. But the transcript says "we announced that NICE had upgraded our status in the U.K." That is a past event, and they are referencing it. But is it described as recent? They say "we announced" in a previous call. On this call, they don't give details. Also, they say "we think that also has a knock-on effect" - that is speculative.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.